Alzamend Neuro, Inc.

NASDAQ:ALZN

1.49 (USD) • At close November 8, 2024
Bedrijfsnaam Alzamend Neuro, Inc.
Symbool ALZN
Munteenheid USD
Prijs 1.49
Beurswaarde 6,668,301
Dividendpercentage 0%
52-weken bereik 1.4 - 19.2
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephan Jackman
Website https://www.alzamend.com

An error occurred while fetching data.

Over Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder,

Vergelijkbare Aandelen

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

8 USD

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

0.99 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

3.76 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.74 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

1.04 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.88 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

19.7 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

1.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)